Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pb-212-CA012
- Development stage
- Unknown
- Lead developer
- German Cancer Research Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Beta-minus Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Pb-212-CA012 (also known as 212Pb-CA012 or 212Pb-PSMA-CA012) is a prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical developed by the German Cancer Research Center (DKFZ) and Heidelberg University. It consists of a Glu-urea-based PSMA-targeting ligand conjugated to the chelator DO3AM via an Amcha linker, radiolabeled with the alpha-emitting radionuclide lead-212 (Pb-212). Lead-212 acts as an in vivo generator of the potent alpha-emitter bismuth-212, delivering highly localized, cytotoxic alpha radiation to PSMA-expressing prostate cancer cells while minimizing damage to surrounding healthy tissues. Pb-212-CA012 is being investigated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), with its elementally matched imaging analogue, Pb-203-CA012, utilized for diagnostic SPECT imaging and dosimetry.
- Other names
- [212Pb]Pb-CA012[212Pb]Pb-PSMA-CA012lead-212 CA012lead212 CA012lead 212 CA012
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on Pb-212-CA012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pb-212-CA012.